Cardiovascular Safety of Concomitant Use of Atypical Antipsychotics and Long-Acting Stimulants in Children and Adolescents With ADHD. Issue 2 (January 2019)

• Record Type: Journal Article
• Authors: Bali, Vishal; Kamble, Pravin S.; Aparasu, Rajender R.
• Is Part Of: Journal of attention disorders. Volume 23:Issue 2(2019)
• Page Start: 163
• Page End: 172
• Publication Date: 2019-01
• Subjects: ADD/ADHD -- stimulants -- atypical antipsychotics -- concomitant use -- polypharmacy -- cardiovascular -- safety -- risk; Attention-deficit hyperactivity disorder -- Periodicals; Attention -- Periodicals; 616.8589
• DOI: 10.1177/1087054715608443
• Languages: English
• ISSNs: 1087-0547

Abstract

Objective: This study examined cardiovascular safety of concomitant use of long-acting stimulants (LAS) and atypical antipsychotics (AAP) in children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD).Method: The study used 2004-2007 IMS LifeLink™ claims data involving 6- to 16-year-old children with ADHD and at least one LAS prescription from July 2004 to December 2006. Time-dependent Cox regression analysis was performed to evaluate the risk of cardiovascular disease (CVD) events due to concomitant use of LAS and AAP.Results: The analytical cohort consisted of 37, 903 children: 538 (1.9%) used LAS and AAP concurrently and the rest used LAS monotherapy. Time-dependent Cox regression analysis revealed no difference in CVD risk among concomitant users of LAS and AAP (hazard ratio = 1.19; 95% confidence interval = [0.60, 2.53]) when compared with users of LAS monotherapy.Conclusion: Concomitant use of LAS and AAP was not associated with risk of CVD events in ADHD patients when compared with LAS monotherapy.